Chong Kun Dang’s Pregrel demonstrates comparable to Plavix

Published: 2008-10-15 06:55:00

Updated: 2008-10-15 06:55:00

The safety and efficacy can be achieved for 300 patients exposing to a high risk of coronary artery disease or its similar disease with Chong Kun Dang’s Pregrel, the generic version of Plavix, a blockbuster blood-thinning drug from Sanofi and Bristol-Myers Squibb Co., new data presented recently ...

Fees

- Email service daily and homepage access.

$300 per month. ($3,240 per year)
5 Email holders per each company.
Anual contract base.

Latest News

Which are outstanding tetravalent vaccines even for the young?

Disease treated the most with clinical trial drugs is respiratory disorder like lung cancer

Who will be the next Pharmaceutical Safety Bureau Director?

Celltrion completes clinical trials for Remsima SC for European approval

Sales listed pharmas made in the first half of the year

TOP

BACK